These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 37606667

  • 1. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S.
    JAMA; 2023 Aug 22; 330(8):746-763. PubMed ID: 37606667
    [Abstract] [Full Text] [Related]

  • 2.
    Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S.
    ; 2023 08 22. PubMed ID: 37669412
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo.
    Zivich PN, Cole SR, Edwards JK, Glidden DV, Das M, Shook-Sa BE, Shao Y, Mehrotra ML, Adimora AA, Eron JJ.
    J Infect Dis; 2024 Apr 12; 229(4):1123-1130. PubMed ID: 37969014
    [Abstract] [Full Text] [Related]

  • 10. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G, Sauermilch D, Gandhi M, Starks TJ.
    AIDS Behav; 2021 Apr 12; 25(4):1299-1305. PubMed ID: 33206262
    [Abstract] [Full Text] [Related]

  • 11. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV, Das M, Dunn DT, Ebrahimi R, Zhao Y, Stirrup OT, Baeten JM, Anderson PL.
    J Int AIDS Soc; 2021 May 12; 24(5):e25744. PubMed ID: 34021709
    [Abstract] [Full Text] [Related]

  • 12. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
    Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, Kiragu M, Reza-Paul S, Myers J, Bekker LG, Yang J, Carter C, de Boer M, Das M, Baeten JM, Celum C.
    JAMA; 2024 Mar 19; 331(11):930-937. PubMed ID: 38427359
    [Abstract] [Full Text] [Related]

  • 13. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
    Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B, HPTN 083 Study Team.
    N Engl J Med; 2021 Aug 12; 385(7):595-608. PubMed ID: 34379922
    [Abstract] [Full Text] [Related]

  • 14. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L, Niu X, Brunelli MK, Mugwanya KK.
    Curr HIV/AIDS Rep; 2024 Oct 12; 21(5):264-281. PubMed ID: 39120667
    [Abstract] [Full Text] [Related]

  • 15. Challenges and Opportunities for Preexposure Prophylaxis.
    Cambou MC, Landovitz RJ.
    Top Antivir Med; 2021 Oct 12; 29(4):399-406. PubMed ID: 34856093
    [Abstract] [Full Text] [Related]

  • 16. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA.
    Drugs; 2022 Sep 12; 82(14):1489-1498. PubMed ID: 36255686
    [Abstract] [Full Text] [Related]

  • 17. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
    US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    JAMA; 2019 Jun 11; 321(22):2203-2213. PubMed ID: 31184747
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
    Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK.
    Pharmacoeconomics; 2024 Apr 11; 42(4):447-461. PubMed ID: 38267806
    [Abstract] [Full Text] [Related]

  • 19. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD.
    Ann Intern Med; 2020 May 05; 172(9):583-590. PubMed ID: 32150602
    [Abstract] [Full Text] [Related]

  • 20. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
    Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, Coelho LE, Phanuphak N, Singh Y, Middelkoop K, Griffith S, McCauley M, Rooney J, Rinehart AR, Clark J, Go V, Sugarman J, Fields SD, Adeyeye A, Grinsztejn B, Landovitz RJ, Safren SA, HPTN 083‐02 Study Team.
    J Int AIDS Soc; 2024 May 05; 27(5):e26252. PubMed ID: 38783534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.